- Home
- SILC vs IMUX Comparison
SILC vs IMUX Comparison
Compare SILC & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | IMUX |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | Israel | United States |
| Employees | N/A | 66 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 75.2M |
| IPO Year | 2002 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SILC | IMUX |
|---|---|---|
| Price | $19.05 | $1.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 38.1K | ★ 4.7M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.44 | $0.51 |
| 52 Week High | $23.00 | $1.51 |
Technical Indicators
Market Signals| Indicator | SILC | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 58.29 |
| Support Level | $18.55 | $0.64 |
| Resistance Level | $21.12 | N/A |
| Average True Range (ATR) | 1.21 | 0.12 |
| MACD | -0.24 | 0.02 |
| Stochastic Oscillator | 8.81 | 51.49 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.